NSE · Healthcare · Diagnostics & Research
EPS came in at 11.47 against a street estimate of 10.57 — a beat of 8.5%.
with an average price target of ₹2,018.08.
| Holder | Stake |
|---|---|
| HDFC Mutual Fund - HDFC Nifty Smallcap 250 ETF | 3.91% |
| Smallcap World Fund, Inc | 2.60% |
| Uti-flexi Cap Fund | 2.49% |
| Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Small Cap Fund | 2.19% |
| Nippon Life India Trustee Ltd-a/c Nippon India Nifty 500 Equal Weight Index Fund | 2.19% |
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 DR. LAL PATHLABS LIMITED – Q1 FY2027 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue: Rs 798 crore in Q1 FY27, up 19.1% YoY (Q1 FY26: Rs 670 crore) — hi | 2026-07-24 |
| Quarterly results · Q1 FY27 DR LAL PATHLABS LIMITED - Q1 FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue: Rs 798 Cr with growth of 19.1% year-on-year • EBITDA: Rs 247 Cr with | 2026-07-24 |
| Annual report FY2026 DR. LAL PATHLABS LIMITED - FY 2025-26 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹27,629 million (12.2% YoY growth) • Reporte | 2026-07-01 |
| Q4 FY26 earnings call DR. LAL PATHLABS LIMITED - Q4 & FY26 EARNINGS SUMMARY HEADLINE NUMBERS • FY26 Revenue: Rs. 2,763 crore, growth of 12.2% (FY25: Rs. 2,461 crore) • Q4 | 2026-05-06 |
| Quarterly results · Q4 FY26 DR LAL PATHLABS LIMITED - FINANCIAL RESULTS SUMMARY Quarter & Year Ended March 31, 2026 --- HEADLINE NUMBERS • Q4 FY26 Revenue: Rs 703 Cr with 16.6 | 2026-04-30 |
| Investor presentation DR. LAL PATHLABS LIMITED – FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue FY26: Rs. 2,763 crore, up 12.2% YoY (FY25: Rs. 2,461 crore) • Q4 FY26 Re | 2026-04-30 |
| Q3 FY26 earnings call DR. LAL PATHLABS LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 revenue: Rs. 660 crore (10.6% YoY growth) vs Rs. 597 crore in Q3 FY25 • 9-mont | 2026-02-03 |
| Quarterly results · Q3 FY26 DR LAL PATHLABS LIMITED – FINANCIAL SUMMARY Q3 & 9-Month Results (December 31, 2025) --- HEADLINE NUMBERS • Q3 FY26 Revenue: Rs 660 Cr (up 10.6% vs | 2026-01-30 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹5 / share ex-date Nov 11, 2026 | 2026-11-11 |
| Dividend | ₹5 / share ex-date Jul 30, 2026 | 2026-07-30 |
| Dividend | ₹4 / share ex-date Jun 25, 2026 · record Jun 26, 2026 | 2026-06-25 |
| Dividend | ₹3.50 / share ex-date Feb 5, 2026 | 2026-02-05 |
| Bonus issue | 1 : 1 ex-date Dec 19, 2025 | 2025-12-19 |
| Dividend | ₹7 / share ex-date Nov 7, 2025 | 2025-11-07 |
| Announcement | Date |
|---|---|
| Second interim dividend of Rs. 5 per equity share declared Dr. Lal Path Labs Ltd. has informed the Exchange that Board of Directors at its meeting held on November 04, 2026, declared 2nd Interim Dividend of Rs. 5 per equity share. | 2026-11-04 |
| Update on acquisition of SHL Diagnostics Dr. Lal PathLabs Limited has completed the acquisition of an 80% stake in Sunshine Healthcare Limited (SHL), a healthcare company based in Ghana. The acquisition was done through the company | 2026-09-26 |
| Acquires 70% stake in SN Genelab Private Limited Dr. Lal PathLabs Limited has announced the acquisition of a 70% stake in SN Genelab Private Limited (SN Gene), a genomics diagnostics company, for up to INR 168 crores with performance-linke | 2026-09-24 |
| Wholly owned subsidiaries approve acquisition of stakes in two companies Dr. Lal PathLabs Ltd., a major Indian diagnostic company, has announced two strategic acquisitions through its wholly-owned subsidiaries: 1. **Sunshine Healthcare Limited (SHL), Ghana**: Dr | 2026-07-24 |
| Interim dividend of Rs. 5 per equity share declared Dr. Lal PathLabs Ltd., a major diagnostic laboratory company, announced an interim dividend of Rs. 5 per equity share approved by its Board of Directors on July 24, 2026. Key Details: - Int | 2026-07-24 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dr. Lal Path Labs Ltd. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.